Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 11/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.45 |
| ▸ | RORA | P35398 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23059982 | 1.00 | GABRA1 (0.50) | GABRA1GABRB2NR1H2NR1H3RORA | |
| SCHEMBL17719304 | 0.91 | GABRA1 (0.43) | GABRA1GABRB2NR1H2NR1H3RORA | |
| SCHEMBL13095523 | 0.89 | GABRA1 (0.41) | GABRA1GABRB2NR1H2NR1H3RORA | |
| SCHEMBL8586265 | 0.87 | NR1H2 (0.48) | NR1H2NR1H3RORAMEN1ALOX15 | |
| SCHEMBL19718414 | 0.86 | GABRA1 (0.39) | GABRA1GABRB2NR1H2NR1H3RORA | |
| SCHEMBL19734501 | 0.82 | ACHE (0.50) | NR1H2NR1H3RORAMEN1ALOX15 | |
| SCHEMBL17717156 | 0.80 | GABRA1 (0.50) | GABRA1GABRB2ALOX15HSD17B10 | |
| SCHEMBL10215034 | 0.80 | MLYCD (0.48) | NR1H2NR1H3MEN1ALOX15TSHR | |
| SCHEMBL18671898 | 0.80 | NR1H2 (0.61) | NR1H2NR1H3RORAMLYCDSMN1; SMN2 | |
| SCHEMBL11884233 | 0.79 | CES2 (0.48) | NR1H2NR1H3MEN1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064690-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-9845319-B2 | Amide substituted thiazoles as modulators of RORyt | Janssen Pharmaceutiuca NV (BE) | 2017-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064690-A1 | THIAZOLES AS MODULATORS OF RORyt | RORC, RORB, RORA | GABRA1 1893/4885GABRB2 2158/4885NR1H2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.